Barclays
TVRD

Barclays’s Tvardi Therapeutics TVRD Stock Holding History

Barclays’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11
Closed -$8K – 7345
2019
Q1 		$8K Buy
+11
New +$6.58K ﹤0.01% 6624
2018
Q4 		– Sell
-33
Closed -$29K – 7415
2018
Q3 		$29K Sell
33
-2,425
-99% -$1.75M ﹤0.01% 6329
2018
Q2 		$1.7M Buy
+2,458
New +$1.25M ﹤0.01% 2726
2017
Q2 		– Sell
-603
Closed -$399K – 6990
2017
Q1 		$399K Buy
+603
New +$322K ﹤0.01% 3627

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Barclays's TVRD Position: Q1 2026 in Review

Barclays reduced its Tvardi Therapeutics (TVRD) stake by 89% in Q1 2026, selling an estimated $28.8K and leaving 946 shares worth $3.01K. The position accounts for ﹤0.01% of the portfolio, ranked #4819.

Barclays first reported a position in TVRD in Q1 2014 and has held it in 46 quarters since. The position peaked at $1.7M in Q2 2018. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Barclays held 946 shares of Tvardi Therapeutics worth $3.01K as of Q1 2026.
  • Barclays sold 7,361 Tvardi Therapeutics shares in Q1 2026, an estimated $28.8K.
  • Tvardi Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4819 holding.
  • Barclays first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 46 quarters since.
  • Barclays's Tvardi Therapeutics position peaked at $1.7M in Q2 2018.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.